FEDERAL COURT OF AUSTRALIA
Roche Therapeutics, Inc v GenRx Pty Ltd [2007] FCA 83
INTELLECTUAL PROPERTY – pharmaceutical patent – interlocutory hearing seeking injunctions to prevent alleged infringement – whether serious question to be tried as to whether there will be infringement – whether patent is invalid – whether impugned products would infringe patent even if valid – where balance of convenience lies
National Health Act 1953 (Cth)
Patents Act 1990 (Cth) ss 7, 18, 117, 138
Therapeutic Goods Act 1989 (Cth)Anaesthetic Supplies Pty Ltd v Rescare Ltd (1994) 50 FCR 1 referred to
Gillette Safety Razor Company v Anglo-American Trading Co Ltd (1913) 30 RPC 465 referred to
Hexal Australia Pty Limited v Roche Therapeutics Inc [2005] FCA 1218 referred to
Re BA’s Application (1915) 32 RPC 348 referred to
Rescare Limited v Anaesthetic Supplies Pty Limited (1992) 25 IPR 119 referred toMacquarie Dictionary, 4th ed, Macquarie University, 2005
Shorter Oxford English Dictionary, 5th ed, Oxford University, 2002Gilbert EM, Olsen SL, Mealey P, Volkman K, Garrabee P, and Bristow MR “Is beta-receptor up-regulation necessary for improved LV function in dilated cardiomyopathy?” (Paper presented at EMH Milan, 1991).
Kelly DT, “Carvedilol in Heart Failure”, Cardiology 1993, 82 (Suppl 3). 45-59.
Metra M, Nardi M, Giubbini R, Dei Cas L, “Effects of Short- and Long- Term Carvedilol Administration on Rest and Exercise Hemodynamic Variables, Exercise Capacity and Clinical Conditions in Patients with Idiopathic Dilated Cardiomyopathy” J Am Coll Cardiol vol 24, no 7, 1994.ROCHE THERAPEUTICS, INC & ORS v GENRX PTY LTD
NSD2429 OF 2006
EMMETT J
9 FEBRUARY 2007
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
NSD2429 OF 2006
BETWEEN:
ROCHE THERAPEUTICS, INC
First ApplicantF HOFFMAN-LA ROCHE AG
Second ApplicantROCHE PRODUCTS PTY LTD
Third ApplicantAND:
GENRX PTY LTD
Respondent
JUDGE:
EMMETT J
DATE OF ORDER:
9 FEBRUARY 2007
WHERE MADE:
SYDNEY
THE COURT:
1.Notes the following undertakings given to the Court by the respondent until further order:
(a)Not to advertise or otherwise promote carvedilol for decreasing mortality resulting from congestive heart failure provided that it will not be a breach of this undertaking for the respondent to advertise or otherwise promote carvedilol in connection with:
(i)Product Information Sheet in the form of Exhibit 1A upon request prior to the approval (if granted) of the Product Information in the form of Exhibit AMK-2; or
(ii) Consumer Medicine Information in the form of Exhibit RM-7.
(b)To prosecute its application for the approval of its Product Information Sheet in the form of Exhibit AMK-2 expeditiously and to inform the applicants at the end of 21 days of the progress of the application.
(c)Not to provide any discount or material benefit to purchasers of carvedilol which is tied to the purchase of any other medicament which is also supplied by any of the applicants in Australia.
(d)Not to provide any discount or material benefit to purchasers of any other medicament which is…
Keep reading for free
Create a free CaseChat account to read Roche Therapeutics, Inc v GenRx Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2007] FCA 83
- Decision Date
CaseChat Overview and Summary
The primary legal issues revolved around whether there was a serious question to be tried regarding the infringement of Roche's patents, and where the balance of convenience lay in granting interlocutory relief. The court had to consider whether the proposed undertakings by GenRx sufficiently protected Roche's interests and whether such relief was warranted at the interlocutory stage.
The Court found that GenRx's undertakings provided adequate protection to Roche's interests, including not advertising carvedilol for reducing mortality except when supplying the unamended product information sheet, maintaining sales records, and ensuring timely prosecution of their application for product information approval. The court concluded that these measures, combined with the balance of convenience, justified the refusal of further interlocutory relief. However, Roche was granted liberty to reapply if circumstances changed significantly. The court also ruled that GenRx's costs of the interlocutory application should be borne by GenRx, without additional orders regarding the costs.
Consequently, upon GenRx providing the specified undertakings, Roche's application for interlocutory relief beyond these undertakings was to be refused. This decision balanced the need to protect Roche's patent rights while considering the potential impact on GenRx's operations and market competition.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Established by: EMMETT J
Congestive heart failure may develop gradually over several years or develop quickly as a result of a heart attack or a disease of the heart muscle. Commonly, patients suffering from congestive heart failure suffer fluid retention. The inadequate blood flow results in the release of hormones that result in the body holding on to sodium and water. In the short term, that leads to an increase in blood volume providing the kidneys with sufficient blood for their normal activity. However, over time, the blood vessels of the body cannot hold all of the extra blood volume and fluid starts to exude out of the blood vessels and into the tissues of the body. Such fluid retention is normally treated with a diuretic drug, which increases urine formation and output. REGISTRATION AND LISTING OF PHARMACEUTICAL GOODS A pharmaceutical product may not be marketed, supplied, offered for sale, sold or distributed within Australia unless it is listed or registered on the Register of Therapeutic Goods maintained under the Therapeutic Goods Act 1989 (Cth). The registration for a pharmaceutical product must include at least one indication for the product within Australia. The Pharmaceutical Benefits Scheme is maintained by the Commonwealth under the National Health Act 1953 (Cth) in order to provide all Australian residents with access to subsidised prescription medicines. The Commonwealth Government will only reimburse retail pharmacies for the difference dispensed price of a product and the patient co-payment if a pharmaceutical product is first listed under the Pharmaceutical Benefits Scheme and is prescribed to the patient in accordance with its listed scheme restriction. An Australian pharmaceutical company that manufactures or distributes pharmaceutical products in Australia, termed a sponsor, may apply for listing of any one or more of its prescription pharmaceutical products under the Pharmaceutical Benefits Scheme. However, a pharmaceutical product must be registered on the Register of Therapeutic Goods before listing can occur under the Pharmaceutical Benefits Scheme. The Schedule of Pharmaceutical Benefits (‘the Schedule’) is published by the Department of Health and Aging. It lists all of the pharmaceutical products included under the Pharmaceutical Benefits Scheme. The schedule sets out pricing information, product strengths and the indication or restriction for the product. The primary purpose of the Schedule is to indicate how pharmaceutical products are priced. In order to obtain listing under the Pharmaceutical Benefits Scheme of an innovative pharmaceutical product that contains a new chemical entity as the active compound, the sponsor must lodge a submission to the Pharmaceutical Benefits Advisory Committee (‘the Advisory Committee’). The Advisory Committee is an independent statutory body with the function of recommending to the Minister the drugs and medicinal preparations for subsidy under the Pharmaceutical Benefits Scheme. Comprehensive guidelines are published for the filing of such a submission, including the information required to support such a submission.